Oyama T, Tomori A, Hotta K, et al. Endoscopic submucosal dissection of early esophageal cancer. Clin Gastroenterol Hepatol. 2005;3:S67–70.
Fujishiro M, Yahagi N, Kakushima N, et al. Endoscopic submucosal dissection of esophageal squamous cell neoplasms. Clin Gastroenterol Hepatol. 2006;4:688–94.
Ishihara R, Iishi H, Uedo N, et al. Comparison of EMR and endoscopic submucosal dissection for en bloc resection of early esophageal cancers in Japan. Gastrointest Endosc. 2008;68:1066–72.
Takahashi H, Arimura Y, Masao H, et al. Endoscopic submucosal dissection is superior to conventional endoscopic resection as a curative treatment for early squamous cell carcinoma of the esophagus (with video). Gastrointest Endosc. 2010;72:255–64.
Katada C, Muto M, Momma K, et al. Clinical outcome after endoscopic mucosal resection for esophageal squamous cell carcinoma invading the muscularis mucosae–a multicenter retrospective cohort study. Endoscopy. 2007;39:779–83.
Shimizu Y, Tsukagoshi H, Fujita M, et al. Long–term outcome after endoscopic mucosal resection in patients with esophageal squamous cell carcinoma invading the muscularis mucosae or deeper. Gastointest Endosc. 2002;56:387–90.
Mizuta H, Nishimori I, Kuratani Y, et al. Predictive factors for esophageal stenosis after endoscopic submucosal dissection for superficial esophageal cancer. Dis Esophagus. 2009;22:626–31.
Katada C, Muto M, Manabe T, et al. Esophageal stenosis after endoscopic mucosal resection of superficial esophageal lesions. Gastrointest Endosc. 2003;57:165–9.
Yano T, Muto M, Minashi K, et al. Photodynamic therapy as salvage treatment for local failures after definitive chemo–radio therapy for esophageal cancer. Gastrointest Endosc. 2005;62:31–6.
The Japanese Society for Esophageal Disease. comprehensive registry of esophageal cancer in Japan, 2009. Esophagus. 2016;13:110–37.
Endo M, Yoshino K, Kawano T, et al. Clinicopathologic analysis of lymph node metastasis in surgically resected superficial cancer of the thoracis esophagus. Dis Esophagus. 2000;13:125–9.
Noguchi H, Naomoto Y, Kondo H, et al. Evaluation of endoscopic mucosal resection for superficial esophageal carcinoma. Surg Laparosc Endosc Percutum Tech. 2000;10:343–50.
Araki K, Ohno S, Egashira A, et al. Pathological feature of superficial esophageal squamous cell carcinoma with lymph node and distal metastasis. Cancer. 2002;94:570–5.
Eguchi T, Nakanishi Y, Shimoda T, et al. Histological criteria for additional treatment after endoscopic mucosal resection for esophageal cancer: analysis of 464 surgically resected cases. Modern Pathol. 2006;19:475–80.
Kim DU, Lee JH, Min BH, et al. Risk factors of lymph node metastasis in T1 esophageal squamous cell carcinoma. J Gastro Hepatol. 2008;23:619–25.
Choi JY, Park YS, Jung HY, et al. Feasibility of endoscopic resection in superficial esophageal squamous carcinoma. Gastrointest Endosc. 2011;73:881–9.
Akutsu Y, Uesato M, Shuto K, et al. The overall prevalence of metastasis in T1 esophageal squamous cell carcinoma: a retrospective analysis of 295 patients. Ann Surg. 2013;257:1032–8.
Tanaka T, Matono S, Mori N, et al. T1 squamous cell carcinoma of the esophagus: long–term outcomes and prognostic factors after esophagectomy. Ann Surg Oncol. 2014;21:932–8.
Barbour AP, Jones M, Brown I, et al. Risk stratification for early esophageal adenocarcinoma: analysis of lymphatic spread and prognostic factors. Ann Surg Oncol. 2010;17:2494–502.
Leers JM, DeMeester SR, Oezcelik A, et al. The prevalence of lymph node metastasis in patients with T1 esophageal adenocarcinoma. A retrospective review of esophagectomy specimens. Ann Surg. 2011;253:271–8.
Merkow RP, Bilimoria KY, Keswani RN, et al. Treatment trends, risk of lymph node metastasis, and outcomes for localized esophageal cancer. J Natl Cancer Inst. 2014;106:dju133.
Yamashina T, Ishihara R, Nagai K, et al. Long term outcome and metastatic risk after endoscopic resection of superficial esophageal squamous cell carcinoma. Am J Gastroenterol. 2013;108:544–51.
Alvarez Herrero L, Pouw RE, van Vilsteren FG, et al. Risk of lymph node metastasis associated with deeper invasion by early adenocarcinoma of the esophagus and cardia: study based on endoscopic resection specimens. Endoscopy. 2010;42:1030–6.
Ancona E, Rampado S, Cassaro M, et al. Prediction of lymph node status in superficial esophageal carcinoma. Ann Surg Oncol. 2008;15:3278–88.
Yamada K, Murakami M, Okamoto Y, et al. Treatment results of chemoradiotherapy for clinical stage I (T1N0M0) esophageal carcinoma. Int J Rad Oncol Biol Phys. 2006;64:1106–11.
Kato H, Sato A, Fukuda H, et al. A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708). Jpn J Clin Oncol. 2009;39:638–43.
Shimizu Y, Kato M, Yamamoto J, et al. EMR combined with chemoradiotherapy: a novel treatment for superficial esophageal squamous–cell carcinoma. Gastrointest Endosc. 2004;59:199–204.
Mayanagi S, Onitsuka T, Nakagawa M, et al. The use of short segment free jejunal transfer as salvage surgery for cervical esophageal and hypopharyngeal cancer. World J Surg. 2014;38:144–9.
Ullah R, Bailie N, Kinsella J, et al. Pharyngo–laryngo–esophagectomy and gastric pull–up for post–cricoid and cervical oesophageal squamous cell carcinoma. J Laryngol Otol. 2002;116:826–30.
Akutsu Y, Kato K, Igaki H, et al. The Prevalence of Overall and Initial Lymph Node Metastases in Clinical T1N0 Thoracic Esophageal Cancer: from the Results of JCOG0502, a Prospective Multicenter Study. Ann Surg. 2016;264:1009–15.
Tachimori Y, Ozawa S, Numasaki H, et al. Registration Committee for Esophageal Cancer of the Japan Esophageal Society. Efficacy of lymph node dissection by node zones according to tumor location for esophageal squamous cell carcinoma. Esophagus. 2016;13:1–7.
Kataoka K, Takeuchi H, Mizusawa J, et al. Japan Esophageal Oncology Group/Japan Clinical Oncology Group. A randomized Phase III trial of thoracoscopic versus open esophagectomy for thoracic esophageal cancer: Japan Clinical Oncology Group Study JCOG1409. Jpn J Clin Oncol. 2016;46:174–7.
Zehr KJ, Dawson PB, Yang SC, et al. Standardized clinical care pathways for major thoracic cases reduce hospital costs. Ann Thorac Surg. 1998;66:914–9.
Low DE, Kunz S, Schembre D, et al. Esophagectomy—it’s not just about mortality anymore: standardized perioperative clinical pathways improve outcomes in patients with esophageal cancer. J gastrointest Surg. 2007;11:1395–402.
Munitiz V, Martinez-de-Haro LF, Ortiz A, et al. Effectiveness of a written clinical pathway for enhanced recovery after transthoracic (Ivor Lewis) oesophagectomy. Br J Surg. 2010;97:714–8.
Fearon KC, Ljungqvist O, Von Meyenfeldt M, et al. Enhanced recovery after surgery: a consensus review of clinical care for patients undergoing colon resection. Clin Nutr. 2005;24:466–77.
Findlay JM, Tustian E, Millo J, et al. The effect of formalizing enhanced recovery after esophagectomy with a protocol. Dis Esophagus. 2015;28:567–73.
Findlay JM, Gillies RS, Millo J, et al. Enhanced recovery for esophagectomy: a systematic review and evidence–based guidelines. Ann Surg. 2014;259:413–31.
Markar SR, Karthikesalingam A, Low DE. Enhanced recovery pathways lead to an improvement in postoperative outcomes following esophagectomy: systematic review and pooled analysis. Dis Esophagus. 2015;28:468–75.
Shewale JB, Correa AM, Baker CM, et al. University of Texas MD Anderson Esophageal Cancer Collaborative Group: impact of a fast–track esophagectomy protocol on esophageal cancer patient outcomes and Hospital charges. Ann Surg. 2015;261:1114–23.
Bleiberg H, Conroy T, Paillot B, et al. Randomised phase II study of cisplatin and 5–fluorouracil (5–FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer. 1997;33:1216–20.
Iizuka T, Kakegawa T, Ide H, et al. Phase II evaluation of cisplatin and 5–fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol. 1992;22:172–6.
Kato K, Muro K, Ando N, et al. The Japan Esophageal Oncology Group of the Japan Clinical Oncology Group (JCOG). A phase II study of nedaplatin and 5–fluorouracil in metastatic squamous cell carcinoma of the esophagus: the Japan Clinical Oncology Group (JCOG) Trial (JCOG 9905–DI). Esophagus. 2014;11:183–8.
Honda M, Miura A, Izumi Y, et al. Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma. Dis Esophagus. 2010;23:641–5.
Hironaka S, Tsubosa Y, Mizusawa J, et al. Japan Esophageal Oncology Group/Japan Clinical Oncology Group. Phase I/II trial of 2–weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807). Cancer Sci. 2014;105:1189–95.
Muro K, Hamaguchi T, Ohtsu A, et al. A phase II study of single–agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol. 2004;15:955–9.
Kato K, Tahara M, Hironaka S, et al. A phase II study of paclitaxel by weekly 1–h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum–based chemotherapy. Cancer Chemother Pharmacol. 2011;67:1265–72.
Jin J, Xu X, Wang F, et al. Second–line combination chemotherapy with docetaxel and nedaplatin for Cisplatin–pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma. J Thorac Oncol. 2009;4:1017–21.
Dutton SJ, Ferry DR, Blazeby JM, et al. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. Lancet Oncol. 2014;15:894–904.
Kudo T, Hamamoto Y, Kato K, et al. Nivolumab treatment for oesophageal squamous–cell carcinoma: an open–label, multicentre, phase 2 trial. Lancet Oncol. 2017;18:631–9.
Herskovic A, Martz K, Al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326:1593–8.
Wong R, Malthaner R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev. 2006;1:CD002092.
Nishimura Y, Ono K, Tsutsui K, et al. Esophageal cancer treated with radiotherapy: impact of total treatment time and fractionation. Int J Radiat Oncol Biol Phys. 1994;30:1099–105.
Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94–05) phase III trial of combined–modality therapy for esophageal cancer: high–dose versus standard–dose radiation therapy. J Clin Oncol. 2002;20:1167–74.
Ando N, Iizuka T, Ide H, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study—JCOG9204. J Clin Oncol. 2003;21:4592–6.
Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5–fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68–74.
Sjoquist KM, Burmeister BH, Smithers BM, et al. Australasian Gastro-Intestinal Trials Group. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta–analysis. Lancet Oncol. 2011;12:681–92.
van Hagen P, Hulshof MC, van Lanschot JJ, et al. CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.
Nakamura K, Kato K, Igaki H, et al. Three–arm phase III trial comparing cisplatin plus 5–FU versus docetaxel, cisplatin plus 5–FU versus radiotherapy with CF (CF–RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT Study). Jpn J Clin Oncol. 2013;43:752–5.
Motoori M, Yano M, Ishihara R, et al. Comparison between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1bN0M0 esophageal cancer. Ann Surg Oncol. 2012;19:2135–41.
Igaki H, Kato H, Tachimori Y, et al. Clinicopathologic characteristics and survival of patients with clinical Stage I squamous cell carcinomas of the thoracic esophagus treated with three–field lymph node dissection. Eur J Cardiothorac Surg. 2001;20:1089–94.
Kawaguchi G, Sasamoto R, Abe E, et al. The effectiveness of endoscopic submucosal dissection followed by chemoradiotherapy for superficial esophageal cancer. Radiat Oncol. 2015;10:31.
Hironaka S, Ohtsu A, Boku N, et al. Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3) N(any) M(0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 2003;57:425–33.
Kato K, Muro K, Minashi K, et al. Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group (JCOG). Phase II study of chemoradiotherapy with 5–fluorouracil and cisplatin for Stage II–III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Rad Onol Biol Phys. 2011;81:684–90.
Kato K, Nakajima TE, Ito Y, et al. Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II–III esophageal carcinoma. Jpn J Clin Oncol. 2013;43:608–15.
Ohtsu A, Boku N, Muro K, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999;17:2915–21.
Ishida K, Ando N, Yamamoto S, et al. Phase II study of cisplatin and 5–fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group Trial (JCOG9516). Jpn J Clin Oncol. 2004;34:615–9.
Nishimura Y, Hiraoka M, Koike R, et al. Long–term follow–up of a randomized Phase II study of cisplatin/5–FU concurrent chemoradiotherapy for esophageal cancer (KROSG0101/JROSG021). Jpn J Clin Oncol. 2012;42:807–12.
Shinoda M, Ando N, Kato K, et al. Randomized study of low–dose versus standard–dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci. 2015;106:407–12.
Higuchi K, Koizumi W, Tanabe S, et al. A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5–fluorouracil (DCF–R) for advanced esophageal carcinoma: kitasato digestive disease & oncology group trial (KDOG 0501). Radiother Oncol. 2008;87:398–404.
Yokota T, Kato K, Hamamoto Y, et al. Phase II study of chemoselection with docetaxel plus cisplatin and 5–fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. Br J Cancer. 2016;155:1328–34.
Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01).Radiation Therapy Oncology Group. JAMA. 1999;281:1623–7.
Wong RK, Malthaner RA, Zuraw L, et al. Cancer Care Ontario Practice Guidelines Initiative Gastrointestinal Cancer Disease Site Group. Combined modality radiotherapy and chemotherapy in nonsurgical management of localized carcinoma of the esophagus: a practice guideline. Int J Radiat Oncol Biol Phys. 2003;55:930–42.
Nishimura Y, Koike R, Ogawa K, et al. Clinical practice and outcome of radiotherapy for esophageal cancer between 1999 and 2003: the Japanese Radiation Oncology Study Group (JROSG) Survey. Int J Clin Oncol. 2012;17:48–54.
Umezawa R, Jingu K, Matsushita H, et al. Long–term results of chemoradiotherapy for stage II–III thoracic esophageal cancer in a single institution after 2000–with a focus on comparison of three protocols. BMC Cancer. 2015;15:813.
Ishikura S, Nihei K, Ohtsu A, et al. Long–term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol. 2003;21:2697–702.
Morota M, Gomi K, Kozuka T, et al. Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma. Int J Radiat Oncol Biol Phys. 2009;75:122–8.
Asakura H, Hashimoto T, Zenda S, et al. Analysis of dose–volume histogram parameters for radiation pneumonitis after definitive concurrent chemoradiotherapy for esophageal cancer. Radiother Oncol. 2010;95:240–4.
Tachimori Y, Kanamori N, Uemura N, et al. Salvage esophagectomy after high–dose chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Cardiovas Surg. 2009;137:49–54.
Swisher SG, Wynn P, Putnam JB, et al. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg. 2002;123:175–83.
Meunier B, Raoul J, Le Prisé E, et al. Salvage esophagectomy after unsuccessful curative chemoradiotherapy for squamous cell cancer of the esophagus. Dig Surg. 1998;15:224–6.
Nakamura T, Hayashi K, Ota M, et al. Salvage esophagectomy after definitive chemotherapy and radiotherapy for advanced esophageal cancer. Am J Surg. 2004;188:261–6.
Takeuchi H, Saikawa Y, Oyama T, et al. Factors influencing the long–term survival in patients with esophageal cancer who underwent esophagectomy after chemoradiotherapy. World J Surg. 2010;34:277–84.
Yano T, Muto M, Hattori S, et al. Long–term results of salvage endoscopic mucosal resection in patients with local failure after definitive chemoradiotherapy for esophageal squamous cell carcinoma. Endoscopy. 2008;40:717–21.
Makazu M, Kato K, Takisawa H, et al. Feasibility of endoscopic mucosal resection as salvage treatment for patients with local failure after definitive chemoradiotherapy for stage IB, II, and III esophageal squamous cell cancer. Dis Esophagus. 2014;27:42–9.
Hatogai K, Yano T, Kojima T, et al. Local efficacy and survival outcome of salvage endoscopic therapy for local recurrent lesions after definitive chemoradiotherapy for esophageal cancer. Radiat Oncol. 2016;11:31.
Katada C, Muto M, Manabe T, et al. Local recurrence of squamous–cell carcinoma of the esophagus after EMR. Gastrointest Endosc. 2005;61:219–25.
Esaki M, Matsumoto T, Hirakawa K, et al. Risk factors for local recurrence of superficial esophageal cancer after treatment by endoscopic mucosal resection. Endoscopy. 2007;39:41–5.
Toyonaga T, Man-i M, East JE, et al. 1,635 Endoscopic submucosal dissection cases in the esophagus, stomach, and colorectum: complication rates and long–term outcomes. Surg Endosc. 2013;27:1000–8.
Urabe Y, Hiyama T, Tanaka S, et al. Metachronous multiple esophageal squamous cell carcinomas and Lugol–voiding lesions after endoscopic mucosal resection. Endoscopy. 2009;41:304–9.
Ono S, Fujishiro M, Niimi K, et al. Long–term outcomes of endoscopic submucosal dissection for superficial esophageal squamous cell neoplasms. Gastrointest Endosc. 2009;70:860–6.
Katada C, Muto M, Tanabe S, et al. Surveillance after endoscopic mucosal resection or endoscopic submucosal dissection for esophageal squamous cell carcinoma. Dig Endosc. 2013;25(Suppl 1):39–43.
Toh Y, Oki E, Minami K, et al. Follow–up and recurrence after a curative esophagectomy for patients with esophageal cancer: the first indicators for recurrence and their prognostic values. Esophagus. 2010;7:37–43.
Kunisaki C, Makino H, Takagawa R, et al. Surgical outcomes in esophageal cancer patients with tumor recurrence after curative esophagectomy. J Gastrointest Surg. 2008;12:802–10.
Sugiyama M, Morita M, Yoshida R, et al. Patterns and time of recurrence after complete resection of esophageal cancer. Surg Today. 2012;42:752–8.
Toh Y, Kitagawa Y, Kuwano H, et al. A nation–wide survey of follow–up strategies for esophageal cancer patients after a curative esophagectomy or a complete response by definitive chemoradiotherapy in Japan. Esophagus. 2016;13:173–81.
Chuang SC, Hashibe M, Scelo G, et al. Risk of second primary cancer among esophageal cancer patients: a pooled analysis of 13 cancer registries. Cancer Epidemiol Biomarkers Prev. 2008;17:1543–9.
Morita M, Saeki H, Ito S, et al. Surgical strategies for esophageal cancer associated with head and neck cancer. Surg Today. 2014;44:1603–10.
Hori K, Okada H, Kawahara Y, et al. Lugol–voiding lesions are an important risk factor for a second primary squamous cell carcinoma in patients with esophageal cancer or head and neck cancer. Am J Gastroenterol. 2011;106:858–66.
Katada C, Tanabe S, Koizumi W, et al. Narrow band imaging for detecting superficial squamous cell carcinoma of the head and neck in patients with esophageal squamous cell carcinoma. Endoscopy. 2010;42:185–90.
Miyata H, Yamasaki M, Kurokawa Y, et al. Survival factors in patients with recurrence after curative resection of esophageal squamous cell carcinomas. Ann Surg Oncol. 2011;18:3353–61.
Kato H, Fukuchi M, Miyazaki T, et al. Classification of recurrent esophageal cancer after radical esophagectomy with two– or three–field lymphadenectomy. Anticancer Res. 2005;25:3461–8.
Abate E, DeMeester SR, Zehetner J, et al. Recurrence after esophagectomy for adenocarcinoma: defining optimal follow–up intervals and testing. J Am Coll Surg. 2010;210:428–35.
Jingu K, Nemoto K, Matsushita H, et al. Results of radiation therapy combined with nedaplatin (cis–diammine–glycoplatinum) and 5–fluorouracil for postoperative locoregional recurrent esophageal cancer. BMC Cancer. 2006;6:50.
Watanabe M, Mine S, Yamada K, et al. Outcomes of lymphadenectomy for lymph node recurrence after esophagectomy or definitive chemoradiotherapy for squamous cell carcinoma of the esophagus. Gen Thorac Cardiovasc Surg. 2014;62:685–92.
Watanabe M, Nishida K, Kimura Y, et al. Salvage lymphadenectomy for cervical lymph node recurrence after esophagectomy for squamous cell carcinoma of the thoracic esophagus. Dis Esophagus. 2012;25:62–6.
Nakamura T, Ota M, Narumiya K, et al. Multimodal treatment for lymph node recurrence of esophageal carcinoma after curative resection. Ann Surg Oncol. 2008;15:2451–7.
Tsuchida E, Sakai K, Matsumoto Y, et al. Concurrent chemoradiotherapy using low–dose continuous infusion of 5–fluorouracil for postoperative regional lymph node recurrence of esophageal squamous cell carcinoma. Esophagus. 2005;2:25–31.
Zhu YL, Li Q, Gao JM, et al. A retrospective evaluation of radiotherapy for the treatment of local esophageal squamous cell carcinoma recurrence after initial complete surgical resection. J Investig Med. 2013;61:34–9.
Baxi SH, Burmeister B, Harvey JA, et al. Salvage definitive chemo–radiotherapy for locally recurrent oesophageal carcinoma after primary surgery: retrospective review. J Med Imaging Radiat Oncol. 2008;52:583–7.
Shioyama Y, Nakamura K, Ohga S, et al. Radiation therapy for recurrent esophageal cancer after surgery: clinical results and prognostic factors. Jpn J Clin Oncol. 2007;37:918–23.
Yamashita H, Nakagawa K, Tago M, et al. Salvage radiotherapy for postoperative loco–regional recurrence of esophageal cancer. Dis Esophagus. 2005;18:215–20.
Ichida H, Imamura H, Yoshimoto J, et al. Pattern of postoperative recurrence and hepatic and/or pulmonary resection for liver and/or lung metastases from esophageal carcinoma. World J Surg. 2013;37:398–407.
Wang S, Tachimori Y, Hokamura N, et al. Prognostic analysis of salvage esophagectomy after definitive chemoradiotherapy for esophageal squamous cell carcinoma: the importance of lymphadenectomy. J Thorac Cardiovasc Surg. 2014;147:1805–11.
Chen Y, Lu Y, Wang Y, et al. Comparison of salvage chemoradiation versus salvage surgery for recurrent esophageal squamous cell carcinoma after definitive radiochemotherapy or radiotherapy alone. Dis Esophagus. 2014;27:134–40.
Takeuchi M, Kobayashi M, Hashimoto S, et al. Salvage endoscopic submucosal dissection in patients with local failure after chemoradiotherapy for esophageal squamous cell carcinoma. Scand J Gastroenterol. 2013;48:1095–101.
Matono S, Fujita H, Tanaka T, et al. Salvage lymphadenectomy without esophagectomy is an option for recurrent or residual lymph nodes after definitive chemoradiotherapy for esophageal cancer. Esophagus. 2014;11:197–203.
Freeman RK, Ascioti AJ, Mahidhara RJ. Palliative therapy for patients with unresectable esophageal carcinoma. Surg Clin North Am. 2012;92:1337–51.
Schweigert M, Dubecz A, Stein HJ. Oesophageal cancer—an overview. Nat Rev Gastroenterol Hepatol. 2013;10:230–44.
Amdal CD, Jacobsen AB, Guren MG, et al. Patient–reported outcomes evaluating palliative radiotherapy and chemotherapy in patients with oesophageal cancer: a systematic review. Acta Oncol. 2013;52:679–90.
Dai Y, Li C, Xie Y, et al. Interventions for dysphagia in oesophageal cancer. Cochrane Database Syst Rev. 2014;10:5048.
Hürtgen M, Herber SC. Treatment of malignant tracheoesophageal fistula. Thorac Surg Clin. 2014;24:117–27.
Margolis M, Alexander P, Trachiotis GD, et al. Percutaneous endoscopic gastrostomy before multimodality therapy in patients with esophageal cancer. Ann Thorac Surg. 2003;76:1694–7.
Naef AP, Savary M, Ozzello L. Columnar–lined lower esophagus: an acquired lesion with malignant predisposition. Report on 140 cases of Barrett’s esophagus with 12 adenocarcinomas. J Thorac Cardiovasc Surg. 1975;70:826–35.
Armstrong D. Review article: towards consistency in the endoscopic diagnosis of Barrett’s oesophagus and columnar metaplasia. Aliment Pharmacol Ther. 2004;20(5):40–7 (discussion 61–2).
Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C and M criteria. Gastroenterology. 2006;131:1392–9.
Spechler SJ, Fitzgerald RC, Prasad GA, et al. History, molecular mechanisms, and endoscopic treatment of Barrett’s esophagus. Gastroenterology. 2010;138:854–69.
Takubo K, Vieth M, Aida J, et al. Differences in the definitions used for esophageal and gastric diseases in different countries: endoscopic definition of the esophagogastric junction, the precursor of Barrett’s adenocarcinoma, the definition of Barrett’s esophagus, and histologic criteria for mucosal adenocarcinoma or high–grade dysplasia. Digestion. 2009;80:248–57.
Riddell RH, Odze RD. Definition of Barrett’s esophagus: time for a rethink—is intestinal metaplasia dead? Am J Gastroenterol. 2009;104:2588–94.